维普中文期刊产品整合服务
8篇 您的检索式:作者名="Eric Lefebvre"
    题名 作者 年代 出处 被引量
1Mouse mastitis model of infection for antimicrobial compound efficacy studies against intracellular and extracellular forms of Staphylococcus aureus显示文摘Brouillette Eric Grondin Gilles Lefebvre Celine 2004Veterinary Microbiology2004,101,4:1
2Foam-coated MIM gives new edge to titanium implants显示文摘Eric Baril Louis-Philippe Lefebvre Yannig Thomas Florin Ilinca 2008Metal Powder Report2008,,8:1
3The impact of story bound entrepreneurial role models on self-efficacy and entrepreneurial intention显示文摘Eric Michael Laviolette Miruna Radu Lefebvre Olivier Brunel 2012International Journal of Entrepreneurial Behaviour & Research2012,,6:1
4Damage Control Resuscitation Is Associated With a Reduction in Resuscitation Volumes and Improvement in Survival in 390 Damage Control Laparotomy Patients显示文摘Bryan A. Cotton Neeti Reddy Quinton M. Hatch Eric LeFebvre Charles E. Wade Rosemary A. Kozar Brijesh S. Gill Rondel Albarado Michelle K. McNutt John B. Holcomb 2011Annals of Surgery2011,,4:1
5Study on the bioequivalence of two formulations of eplerenone in healthy volunteers under fasting conditions: data from a single-center, randomized, single-dose, open-label, 2-way crossover bioequivalence study显示文摘Susana Almeida Pedro Pedroso Augusto Filipe Catarina Pinho Rita Neves Cintia Jiménez Eric Sicard Marc Lefebvre 2011Arzneimittelforschung2011,,03:1
6POWER1和2试验中对曾治疗HIV-1感染患者给予地瑞那韦-利托那韦治疗48周时的疗效与安全性:2项随机试验资料的合并亚组分析显示文摘背景连续、随机、多国性POWER1和2ⅡB期研究旨在评价地瑞那韦(darunavir)联合应用小剂量利托那韦(ritonavir)对曾治疗HIV-1感染患者的疗效与安全性。本文作者进行了一项合并的亚组分析,对接受推荐剂量地瑞那韦-利托那韦的患者与接受其他蛋白酶抑制剂(PI)的患者进行比较,以提供治疗48周时有关疗效与安全性的最新信息。 方法在24周的剂量探索期和主要疗效分析后,被随机分入地瑞那韦-利托那韦组的患者继续服药600/100mg2次/d.而对照PI组的患者继续按指定治疗方案进入较长期的开放标记期;所有患者继续接受最佳背景治疗。对在分析时已达到第48周或提前停药的患者进行了评估;地瑞那韦~利托那韦组只纳入了从基线开始就服用600/100mg2次/d的患者。采用意向性治疗分析。POWER2研究(TMC114-C202)在ClinicalTrials.gov注册(NCT00071097)。结果48周时,110例地瑞那韦-利托那韦组患者中有67例(61%)病毒载量较基线下降≥1 log10拷贝/ml,而120例对照PI组患者中仅有18例(15%)(主要终点;反应率差值46%,95%CI35%~57%,P〈0,0001)。根据logisticS/归模型,该模型将分层因素(基线时原发PI突变数、恩夫韦地的使用、基线病毒载量)和研究作为协变量,反应率差值为50%(OR 11.72,95%CI 5.75~23.89)。在地瑞那韦-利托那韦组,如果校正治疗暴露,则不良事件率大都低于或近似于对照组。没有发现意外的安全事件。 结论采用地瑞那韦-利托那韦600/100mg 2次/d加最佳背景治疗的疗效反应大于对照PI。且疗效至少持续48周,尤其在曾治疗HIV患者中具有良好的安全性和耐受性。这一方案扩展了此类患者的治疗选择。Bonaventura Claret Nicholas Bellos Jean-Michel Molina David Cooper Jean-Christophe Goffard Adriano Lazzarin Andrej Wohrmann Christine Katlama Timothy Wilkin Richard Haubrich Calvin Cohen Charles Farthing Dushyantha Jayaweera Martin Markowitz Peter Ruane Sabrina Spinosa-Guzman Eric Lefebvre 王介明(译) 李宏建(译) 2008世界临床医学2008,2,2:0
7Should medium-sized contractors still implement home-made information technologies on construction sites?显示文摘Despite the increasing dissemination of the Building Information Modeling(BIM)approach,many firms are still far from BIM and are only starting to adopt information technologies.We conducted an ethnographic action research with an industrial partner that implements information technologies on its construction sites,with a strong preference for home-made applications.Results show that the development of such applications faces difficulties and that multiple iterations and versions are necessary before achieving the expected goals because the required competencies are lacking among internal development teams.Moreover,initial needs evolve considerably throughout the application’s development and evaluation process.However,notwithstanding the difficulties encountered during the different application development phases,the industrial partner believes the decision to be worthwhile because of the desire to have internal control over the project data and the need to consider certain specificities related to business processes.Conrad BOTON Eric ST-PIERRE Gabriel LEFEBVRE 2020Frontiers of Engineering Management2020,7,1:0
8法国博物馆的保存修复管理:博物馆体制内的保存修复策略显示文摘尊敬的各位来宾,朋友们:首先,我要感谢会议的主办方,感谢中国美术馆的馆长和同道邀请我来参加这次研讨会。法国博物馆的文物保护管理如何在一个制度框架内制定博物馆的文物保护战略是我想探讨的内容。在讲这个话题之前,我想强调一个事实,我自己本身不是修复师,也不是科学家,我的朋友宝琳女士是纸质作品的修复师,她更能代表法国的修复师。明天她将在演讲中为大家介绍法国在纸质藏品保护方面所做的工作。Eric Lefebvre 2016中国美术馆2016,0,5:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费